181 related articles for article (PubMed ID: 36120843)
1. CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer.
Chen Y; Xu T; Jiang C; You S; Cheng Z; Gong J
Acta Radiol; 2023 Apr; 64(4):1390-1399. PubMed ID: 36120843
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
4. A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
Zhou J; Zou S; Kuang D; Yan J; Zhao J; Zhu X
Front Oncol; 2021; 11():769272. PubMed ID: 34868999
[TBL] [Abstract][Full Text] [Related]
5. A Radiomics Signature in Preoperative Predicting Degree of Tumor Differentiation in Patients with Non-small Cell Lung Cancer.
Chen X; Fang M; Dong D; Wei X; Liu L; Xu X; Jiang X; Tian J; Liu Z
Acad Radiol; 2018 Dec; 25(12):1548-1555. PubMed ID: 29572049
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
7. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
8. Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
Cong M; Feng H; Ren JL; Xu Q; Cong L; Hou Z; Wang YY; Shi G
Lung Cancer; 2020 Jan; 139():73-79. PubMed ID: 31743889
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a CT-Based Signature for the Prediction of Distant Metastasis Before Treatment of Non-Small Cell Lung Cancer.
Tao J; Lv R; Liang C; Fang J; Liu D; Lan X; Huang H; Zhang J
Acad Radiol; 2022 Feb; 29 Suppl 2():S62-S72. PubMed ID: 33402298
[TBL] [Abstract][Full Text] [Related]
10. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer.
Su GH; Xiao Y; Jiang L; Zheng RC; Wang H; Chen Y; Gu YJ; You C; Shao ZM
J Transl Med; 2022 Oct; 20(1):471. PubMed ID: 36243806
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Wen Q; Yang Z; Zhu J; Qiu Q; Dai H; Feng A; Xing L
Onco Targets Ther; 2020; 13():12003-12013. PubMed ID: 33244242
[TBL] [Abstract][Full Text] [Related]
12. Elaboration of Multiparametric MRI-Based Radiomics Signature for the Preoperative Quantitative Identification of the Histological Grade in Patients With Non-Small-Cell Lung Cancer.
Tang X; Bai G; Wang H; Guo F; Yin H
J Magn Reson Imaging; 2022 Aug; 56(2):579-589. PubMed ID: 35040525
[TBL] [Abstract][Full Text] [Related]
13. Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images.
Chen L; Chen L; Ni H; Shen L; Wei J; Xia Y; Yang J; Yang M; Zhao Z
Front Oncol; 2023; 13():1104316. PubMed ID: 36860311
[TBL] [Abstract][Full Text] [Related]
14. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
Yang F; Zhang J; Zhou L; Xia W; Zhang R; Wei H; Feng J; Zhao X; Jian J; Gao X; Yuan S
Eur Radiol; 2022 Mar; 32(3):1538-1547. PubMed ID: 34564744
[TBL] [Abstract][Full Text] [Related]
15. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
16. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
17. Enhancing brain metastasis prediction in non-small cell lung cancer: a deep learning-based segmentation and CT radiomics-based ensemble learning model.
Gong J; Wang T; Wang Z; Chu X; Hu T; Li M; Peng W; Feng F; Tong T; Gu Y
Cancer Imaging; 2024 Jan; 24(1):1. PubMed ID: 38167564
[TBL] [Abstract][Full Text] [Related]
18. Application of radiomics based on chest CT-enhanced dual-phase imaging in the immunotherapy of non-small cell lung cancer.
Ma ZP; Li XL; Gao K; Zhang TL; Wang HD; Zhao YX
J Xray Sci Technol; 2023; 31(6):1333-1340. PubMed ID: 37840466
[TBL] [Abstract][Full Text] [Related]
19. Radiomics of
Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
[TBL] [Abstract][Full Text] [Related]
20. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.
Tong H; Sun J; Fang J; Zhang M; Liu H; Xia R; Zhou W; Liu K; Chen X
Front Immunol; 2022; 13():859323. PubMed ID: 35572597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
